ContraVir is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. The company currently has two novel, liver-targeting compounds in clinical development. CRV431 is a cyclophilin inhibitor that targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. CRV431 additionally shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease. TXL™ is a direct acting antiviral (DAA) nucleotide analog lipid prodrug of tenofovir (TFV) that potently inhibits replication of hepatitis B virus. The prodrug design of TXL™ results in more efficient delivery of the active tenofovir species (tenofovir diphosphate) to the liver which is predicted to result in fewer off-target side-effects. The multiple mechanisms of action of CRV431 and TXL™ equate to many therapeutic opportunities for alleviating the life-threatening risks of liver disease.